OTCMKTS:QBIO Q BioMed (QBIO) Stock Price, News & Analysis → The Best Stock Trading for Less Than $10 Per Share? (From Eagle Publishing) (Ad) Free QBIO Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume2,400 shsAverage Volume18,853 shsMarket Capitalization$10,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsStock AnalysisChartEarningsFinancialsSEC Filings Get Q BioMed alerts: Email Address Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. About Q BioMed Stock (OTCMKTS:QBIO)Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.Read More Ad Porter & CompanyThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. QBIO Stock News HeadlinesMarch 11, 2024 | msn.comClearside Biomedical Q4 2023 Earnings PreviewFebruary 24, 2024 | benzinga.comQ BioMed Stock (OTC:QBIO) Dividends: History, Yield and DatesFebruary 13, 2024 | msn.comBiogen Inc. (BIIB) Lags Q4 Earnings and Revenue EstimatesJanuary 28, 2024 | msn.comBioxyne’s Q2 FY24 revenue surpasses $2.5m on Aussie medicinal cannabis growthNovember 16, 2023 | morningstar.comQ BioMed Inc QBIOAugust 18, 2023 | seekingalpha.comQBIO Q BioMed Inc.April 14, 2023 | proactiveinvestors.comQ BioMed receives US patent and notice of allowance in Europe for Uttroside B; seeks ways to boost shareholder valueApril 14, 2023 | finance.yahoo.comQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for EuropeMarch 3, 2023 | benzinga.comQ BioMed Stock (OTC:QBIO), Quotes and News SummaryFebruary 10, 2023 | proactiveinvestors.comQ BioMed gets notice of allowable US patent for liver cancer treatment Uttroside BFebruary 10, 2023 | finance.yahoo.comQ BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent OfficeJanuary 12, 2023 | benzinga.comShort Volatility Alert: Q Biomed IncJanuary 1, 2023 | finance.yahoo.comQ BioMed Inc. (QBIO)November 14, 2022 | proactiveinvestors.comQ BioMed boosted by multi-million dollar asset as it converts long-term royalty into equity stake in Mannin ResearchNovember 14, 2022 | finance.yahoo.comQ BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.October 11, 2022 | prnewswire.comQ BIOMED PROVIDES SHAREHOLDER UPDATESeptember 27, 2022 | proactiveinvestors.comQ Biomed announces patent for groundbreaking GDF15 biomarker for glaucoma detection and treatmentSeptember 27, 2022 | finance.yahoo.comQ BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKERAugust 25, 2022 | finance.yahoo.comTraders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.July 29, 2022 | finance.yahoo.comQ BioMed Inc. Provides Update to ShareholdersJuly 26, 2022 | proactiveinvestors.comQ BioMed welcomes study that highlights the safety and efficacy of Uttroside-B chemotherapeuticJuly 26, 2022 | finance.yahoo.comQ BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancerMay 11, 2022 | investing.comQ BioMed Inc (QBIO)May 6, 2022 | proactiveinvestors.comQ BioMed says its strategy is paying off as it outlines its value proposition in multibillion-dollar marketsMay 6, 2022 | finance.yahoo.comQ BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar MarketsSee More Headlines Receive QBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q BioMed and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/14/2021Today6/14/2024Fiscal Year End11/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:QBIO Previous SymbolNASDAQ:QBIO CUSIPN/A CIK1596062 Webwww.qbiomed.com Phone(646) 889-2226FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$280,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / BookN/AMiscellaneous Outstanding Shares145,100,000Free Float104,178,000Market Cap$10,000.00 OptionableNot Optionable Beta2.26 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Denis D. Corin (Age 51)Chairman, CEO & President Comp: $300kMr. William S. Rosenstadt (Age 56)Chief Legal Officer, General Counsel & Director Comp: $300kKey CompetitorsSunwin Stevia InternationalOTCMKTS:SUWNWellness Center USAOTCMKTS:WCUIAdhera TherapeuticsOTCMKTS:ATRXStatera BiopharmaNASDAQ:STABBohai Pharmaceuticals GroupOTCMKTS:BOPHView All Competitors QBIO Stock Analysis - Frequently Asked Questions How were Q BioMed's earnings last quarter? Q BioMed Inc. (OTCMKTS:QBIO) issued its quarterly earnings results on Wednesday, July, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.04. The business earned $0.05 million during the quarter. What other stocks do shareholders of Q BioMed own? Based on aggregate information from My MarketBeat watchlists, some companies that other Q BioMed investors own include NVIDIA (NVDA), Micron Technology (MU), Washington Trust Bancorp (WASH), Nokia Oyj (NOK), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Intel (INTC), OPKO Health (OPK) and AT&T (T). How do I buy shares of Q BioMed? Shares of QBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:QBIO) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White Hous...Stansberry Research | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q BioMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.